In our study, we demonstrated that hAMSCs inhibit proliferation and promote apoptosis of Hepg2 cells through blocking both Wnt/β‐catenin and IGF‐1R/PI3K/AKT signalling pathways, suggesting that administration of hAMSCs and hAMSC‐CM may be a novel strategy for treatment of HCC clinically. Here, IGF1R is linked to hepatocellular carcinoma.